Healthcare - Biotechnology - NASDAQ - US
$ 1.08
-4.42 %
$ 1.16 M
Market Cap
0.0
P/E
CASH FLOW STATEMENT
-8.72 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
5.96 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ZyVersa Therapeutics, Inc.
| Net Income | -98.3 M |
| Depreciation & Amortization | 10.4 K |
| Capital Expenditures | -1 |
| Stock-Based Compensation | 1.19 M |
| Change in Working Capital | 2.6 M |
| Others | 95.4 M |
| Free Cash Flow | -8.72 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (98.3) | (14.0) | (8.1) | (12.7) |
| Depreciation & Amortization | 10.4 K | 9.87 K | 10.4 K | 10.4 K |
| Deferred Income Tax | (9.5) | (0.7) | (0.4) | 0.3 |
| Stock Based Compensation | 1.2 | 3.5 | 4.1 | 3.8 |
| Other Operating Activities | 95.3 | 1.5 | 0.3 | 0.3 |
| Change in Working Capital | 2.6 | 8.3 | (1.0) | 3.1 |
| Cash From Operations | (8.7) | (1.5) | (5.1) | (5.1) |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | 1 | 0 | 0 | 0 |
| Other Items | 1 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | (10.7) | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 1.7 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (12.2) | 2.0 | 5.2 | (0.1) |
| Cash From Financing Activities | 6.0 | 1.87 K | 5.2 | 4.6 |
| CHANGE IN CASH | ||||
| Net Change In Cash | (2.8) | 0.4 | 0.2 | (0.5) |
| FREE CASH FLOW | ||||
| Free Cash Flow | (8.7) | (1.5) | (5.1) | (5.1) |